We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Meanwhile, two oral CGRP inhibitors – AbbVie’s Ubrelvy and BioHaven’s Nurtec – have been launched for the on-demand treatment of acute migraine attacks. These don’t compete with Aimovig ...

Pharma giant Pfizer has agreed to pay $59 million to settle a federal lawsuit accusing a local biopharmaceutical company of paying “kickbacks” to healthcare providers to induce them to prescribe its ...

Nurtec ODT/Vydura globally, up 39% operationally, driven primarily by strong demand in the U.S. and, to a much lesser extent, recent launches in international markets, partially offset by lower ...

odfdo is a derivative work of the former lpod-python project. About styles: the best way to apply style is by merging styles from a template document into your generated document (See odfdo-styles ...

10 luxury brand logos have mastered it. They've become more than marks on products—they're cultural touchstones, over decades and continents. Logos are stories we tell ourselves. The best ones?

Nebraska will receive $62,688.71. Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine medication. The company also paid some ...

Pfiz­er will pay near­ly $60 mil­lion to set­tle claims that its sub­sidiary Bio­haven used il­le­gal kick­backs to dri­ve sales of its mi­graine med­i­cine Nurtec ODT … ...

The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...

The settlement resolves allegations that Biohaven paid improper remuneration, including speaker honoraria and high-end restaurant meals, to physicians and other healthcare professionals to promote ...